Immune (idiopathic) thrombocytopenic purpura with COVID-19 infection diagnosed in pregnancy and management: a case report

Authors

  • Bendangtoshi Jamir Department of Obstetrics and Gynecology, Christian Institute of Health Sciences and Research, Dimapur, Nagaland, India
  • Kanili Jimo Department of Obstetrics and Gynecology, Christian Institute of Health Sciences and Research, Dimapur, Nagaland, India
  • Nounechutuo Miachieo Department of Pathology, Christian Institute of Health Sciences and Research, Dimapur, Nagaland, India
  • Vivek Thapa Department of Medicine, Christian Institute of Health Sciences and Research, Dimapur, Nagaland, India
  • Rebeki Momin Department of Obstetrics and Gynecology, Christian Institute of Health Sciences and Research, Dimapur, Nagaland, India

DOI:

https://doi.org/10.18203/2320-1770.ijrcog20222505

Keywords:

Immune thrombocytopenic purpura, Idiopathic thrombocytopenic purpura, Pregnancy, Management

Abstract

Immune (idiopathic) thrombocytopenic purpura (ITP), an autoimmune disease characterized by destruction of platelets, is a hematological disorder that can present in both pregnant and non-pregnant patients. It can occur in any trimester but generally, platelet counts start to decline in early pregnancy and continue to decline until delivery. Unlike most pregnancy-related thrombocytopenia, which is usually mild, ITP can have devastating consequences for mother, fetus, and neonate. It is a diagnosis of exclusion, and management should be based on a multidisciplinary care approach. ITP in pregnancy requires careful monitoring and may need treatment to improve platelet counts before delivery. Corticosteroid is the most commonly used first-line therapy to stop further destruction of platelets. Here, we report a case of a 26-year-old multigravida with gestational age of 24 weeks, diagnosed with ITP during routine antenatal check-up. Patient was managed with various treatment combinations consisting of platelet transfusion, steroids and intravenous immunoglobulin (IVIG) to reach the optimal platelet level. The aim of the study was to provide guidance on how to manage a patient with ITP throughout pregnancy

Metrics

Metrics Loading ...

Author Biography

Bendangtoshi Jamir, Department of Obstetrics and Gynecology, Christian Institute of Health Sciences and Research, Dimapur, Nagaland, India

Consultant, department of obstetrics and Gynaecology

References

Asif N, Hassan K. Thrombocytopenia in Pregnancy. Hematology and Transfusion. Int J. 2012;5:1-4.

Baucom AM, Kuller JA, Dotters-Katz S. Immune Thrombocytopenic Purpura in Pregnancy. Obstet Gynecol Surv. 2019;74(8):490-6.

Huang E, Tan L. Immune Thrombocytopenia Purpura Diagnosed in Pregnancy: A Case Report and Review of Management. J Med Cas. 2015;6(8):358-61.

Crae K. Thrombocytopenia in pregnancy. In: Michelson A, eds. Platelets. New York: Elsevier; 2006.

George JN, Woolf SH, Raskob GE, Wasser JS, Aledort LM, Ballem PJ, et al. Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. Blood. 1996;88(1):3-40.

British Committee for Standards in Haematology General Haematology Task Force. Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and in pregnancy. Br J Haematol. 2003;120(4):574-96.

Stavrou E, McCrae KR. Immune thrombocytopenia in pregnancy. Hematol Oncol Clin North Am. 2009;23(6):1299-316.

Downloads

Published

2022-09-27

How to Cite

Jamir, B., Jimo, K., Miachieo, N., Thapa, V., & Momin, R. (2022). Immune (idiopathic) thrombocytopenic purpura with COVID-19 infection diagnosed in pregnancy and management: a case report. International Journal of Reproduction, Contraception, Obstetrics and Gynecology, 11(10), 2906–2909. https://doi.org/10.18203/2320-1770.ijrcog20222505

Issue

Section

Case Reports